BioReperia secured $900k in capital investment from Hemex.

BioReperia, a Linköping, Sweden-based company that developed a unique zebrafish technology platform helping with reducing cancer mortality, announced closing a SEK 8M ($860k) capital investment round.

The money was provided by Swiss strategic investor Hemex and included existing and new business angels from Switzerland, Germany and Sweden.

BioReperia, founded in 2015 and led by CEO Anna Fahlgren, built a method in which the patient's own cancer cells are placed in zebrafish embryos, and thusly can predict the most effective cancer treatment for individual patients.

The company's zebrafish model is already used today for drug development in the Nordic countries and Switzerland. Through the method, pharmaceutical companies can reduce the time radically for the development of new pharmaceutical substances and thus save a lot of time and costs.

BioReperia is also backed by the Linköping University.